Altre lingue Marinus Pharmaceuticals, Inc. London S.E.

Azioni

0JYL

US56854Q2003

Mercato chiuso - London S.E. Altri mercati azionari 15:50:38 04/02/2021			Variaz. 5gg	Var. 1 gen.
13,97 ^USD	-0,43%		+800,77%	+25,84%

17/06	Aggiornamento settoriale: i titoli del settore sanitario scendono lunedì prima del mercato	MT
17/06	I principali ribassisti del mercato premarket	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit	20/06
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)	20/06
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)	18/06
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors	17/06
Sector Update: Health Care Stocks Decline Premarket Monday	17/06
Top Premarket Decliners	17/06
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study	17/06
Marinus Pharmaceuticals : Corporate Overview Slide Deck	17/06
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus	17/06
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus	17/06
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS	15/06
Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS	15/06
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors	14/06
Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit	14/06
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	13/06
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit	13/06
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	13/06
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors	13/06
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors	13/06
Law Offices of Howard G. Smith Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors	13/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Marinus Pharmaceuticals, Inc. London S.E.

Azioni

0JYL

US56854Q2003

Altre lingue

Filtri